CERo Zooms on Cell Developments
CERo Therapeutics Holdings, Inc. (NASDAQ: CERO) shares jumped into the green Monday. The San Francisco-based company, an immunotherapy concern developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236.
Following an evaluation from the trial’s Dose Escalation Safety Committee, preliminary results show that the patient demonstrated no dose limiting toxicity. The Company anticipates dosing the second patient in the cohort shortly.
CERo CMO Robert Sikorski MD., PhD. noted,
“The first patient experienced no dose-limiting toxicities during the planned 28-day observation period following the successful manufacturing of CER-1236 from an AML patient. A second AML patient has been identified and has provided informed consent for participation in the trial.”
CER-1236 is currently in Phase 1 clinical trials for AML. The first-in-human, multi-center, open label, Phase 1/1b study, titled, “Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia (CertainT-1),” is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with acute myeloid leukemia that is either relapsed/refractory, or in remission with measurable residual disease, or newly diagnosed patients with TP53 mutated MDS/AML or AML.
CERO shares hiked 45 cents, or 4.2%, to begin Monday at $11.13.
